Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 233

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors

Open access
Xu, Danyan, Li, Ning, He, Yuxia, Timofeyev, Valeriy, Lu, Ling, Tsai, Hsing-Ju, Kim, In-Hae, Tuteja, Dipika, Mateo, Robertino Karlo P., Singapuri, Anil, Davis, Benjamin B., Low, Reginald, Hammock, Bruce D., Chiamvimonvat, Nipavan·2006·Proceedings of the National Academy of Sciences

Abstract

Sustained cardiac hypertrophy represents one of the most common causes leading to cardiac failure. There is emerging evidence to implicate the involvement of NF-κB in the development of cardiac hypertrophy. However, several critical questions remain unanswered. We tested the use of soluble epoxide hydrolase (sEH) inhibitors as a means to enhance the biological activities of epoxyeicosatrienoic acids (EETs) to treat cardiac hypertrophy. sEH catalyzes the conversion of EETs to form the corresponding dihydroxyeicosatrienoic acids. Previous data have suggested that EETs may inhibit the activation of NF-κB-mediated gene transcription. We directly demonstrate the beneficial effects of several potent sEH inhibitors (sEHIs) in cardiac hypertrophy. Specifically, we show that sEHIs can prevent the development of cardiac hypertrophy using a murine model of pressure-induced cardiac hypertrophy. In addition, sEHIs reverse the preestablished cardiac hypertrophy caused by chronic pressure overload. We further demonstrate that these compounds potently block the NF-κB activation in cardiac myocytes. Moreover, by using in vivo electrophysiologic recordings, our study shows a beneficial effect of the compounds in the prevention of cardiac arrhythmias that occur in association with cardiac hypertrophy. We conclude that the use of sEHIs to increase the level of the endogenous lipid epoxides such as EETs may represent a viable and completely unexplored avenue to reduce cardiac hypertrophy by blocking NF-κB activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0609158103

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 233

Metadata

Authors
Xu, D., Li, N., He, Y., Timofeyev, V., Lu, L., Tsai, H.-J., Kim, I.-H., Tuteja, D., Mateo, R. K. P., Singapuri, A., Davis, B. B., Low, R., Hammock, B. D., & Chiamvimonvat, N.
Venue
Proceedings of the National Academy of Sciences
Published
2006-12-05
Volume
103
Issue
49
Pages
18733-18738
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2047786869
Cited by
233
References
2
FWCI
4.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. https://app.cochat.ai/papers/10.1073/pnas.0609158103
The paper
Xu, D., Li, N., He, Y., Timofeyev, V., Lu, L., Tsai, H.-J., Kim, I.-H., Tuteja, D., Mateo, R. K. P., Singapuri, A., Davis, B. B., Low, R., Hammock, B. D., & Chiamvimonvat, N. (2006). Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0609158103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.